Kamada (KMDA) Common Equity (2012 - 2026)
Kamada's (KMDA) quarterly Common Equity came in at $269.6 million in Q2 2026, up 3.69% on a YoY basis from $260.0 million in Q2 2025, and up 3.92% quarter-over-quarter from $259.4 million in Q1 2026.
Analysis
Kamada (KMDA) Common Equity (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Common Equity for 15 consecutive years, with $269.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Common Equity rose 3.69% year-over-year to $269.6 million; the trailing twelve-month figure through Jun 2026 stood at $269.6 million (up 3.69% YoY), and the FY2025 full-year result was $269.1 million, up 3.7% from the prior year.
- Common Equity improved to $269.6 million in Q2 2026 per KMDA's latest filing, from $259.4 million in the prior quarter.
- Across five years, Common Equity topped out at $269.6 million in Q2 2026 and bottomed at $171574.0 in Q2 2022.
- Historically, Common Equity has averaged $219.4 million across 5 years, with a median of $251.2 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Common Equity tumbled 99.91% in 2022, then soared 102917.94% in 2023.
- Over 5 years, Common Equity stood at $176.0 million in 2022, then surged by 38.63% to $244.0 million in 2023, then increased by 6.33% to $259.5 million in 2024, then rose by 3.7% to $269.1 million in 2025, then climbed by 0.18% to $269.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $269.6 million, $259.4 million, and $269.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 269.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 269.56 Mn |
| Mar 31, 2026 | 259.39 Mn |
| Dec 31, 2025 | 269.07 Mn |
| Sep 30, 2025 | 265.23 Mn |
| Jun 30, 2025 | 259.95 Mn |
| Mar 31, 2025 | 251.96 Mn |
| Dec 31, 2024 | 259.46 Mn |
| Sep 30, 2024 | 255.27 Mn |
| Jun 30, 2024 | 251.15 Mn |
| Mar 31, 2024 | 251.15 Mn |
| Dec 31, 2023 | 244.02 Mn |
| Sep 30, 2023 | 238.39 Mn |
| Jun 30, 2023 | 176.75 Mn |
| Mar 31, 2023 | 174.81 Mn |
| Dec 31, 2022 | 176.02 Mn |
| Sep 30, 2022 | 172.55 Mn |
| Jun 30, 2022 | 171,574.00 |
| Mar 31, 2022 | 175.15 Mn |
| Dec 31, 2021 | 176.82 Mn |
| Sep 30, 2021 | 181.61 Mn |